Q4 total and net product revenues are estimated to be between $7.5M to $8.2M and $6.9M to $7.6M, respectively.
For FY 2019, total and net product revenues are estimated between $19.3M to $20M and $15.8M to $16.5M, respectively.
Q4 and FY 2019 YUTIQ revenue between $4.1M – $4.5M and $11.4 – $11.8M, respectively.
Q4 and FY 2019 DEXYCU revenue between $2.8M to $3.1M and $4.4M to $4.7M, respectively.
The company will host a conference call and
webcast to discuss Q4 and FY 2019 financial results on Thursday, March
5, 2020 at 8:30 AM ET.
Shares are up 15% premarket.
https://seekingalpha.com/news/3533876-eyepoint-pharmaplus-15-premarket-on-preliminary-2019-revenues
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.